TAK-834-4008: Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA® (Parathyroid Hormone) for Injection, for Subcutaneous Use (NATPARA KAB)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/49588
• EU PAS number:
  EUPAS48713
• Study ID:
  49588
• Official title and acronym:
  TAK-834-4008: Quantitative Testing of Patient and Healthcare Provider Knowledge, Attitudes, and Behavior About NATPARA® (Parathyroid Hormone) for Injection, for Subcutaneous Use (NATPARA KAB)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This main aim of this study is to check level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of NATPARA. The survey will be done via internet, telephone, or paper and participants will be able to choose the method that is preferred.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Shire

Study timelines

Date when funding contract was signed

Actual: 01/09/2015

Study start date

Actual: 01/09/2015

Date of final study report

Planned: 31/01/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Shire

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only

Other study registration identification numbers and links

NCT05556629 - https://clinicaltrials.gov/ct2/show/NCT05556629,,https://clinicaltrials.takeda.com/study-detail/7e4fd13264a44033?idFilter=%5B%22TAK-834-4008%22%5D